Hexane insoluble fraction—an anthocyanin-rich extract from purple rice—presented the anti-prostatic hyperplasia effects in the testosterone implanted rat model.
The preventive effects of purple rice crude ethanolic extract (PRE) were firstly investigated on testosterone‐induced benign prostatic hyperplasia (BPH) in castrated rats. As compared to vehicle‐treated rats, lower prostate weights were found in the BPH rats that received PRE 1 g/kg bw. In addition, the PRE treatment down‐regulated the androgen receptor (AR) expression in the dorsolateral prostate of those rats. In human prostate cancer cell line, LNCaP, PRE could reduce the cell growth, down‐regulate the expression of AR and suppress prostate‐specific antigen (PSA) secretion. Moreover, PRE also inhibited an activity of 5α‐reductase from rat liver microsomes and the mutagenicity of Salmonella Typhimurium induced by standard mutagen. These results demonstrate that PRE altered testosterone‐induced BPH in rats and retarded prostate cancer cell growth by modulating AR expression. It is therefore recommended that further investigation is undertaken into the chemopreventive potential of PRE in androgen‐AR mediated diseases.
Practical applications
This study revealed the mechanisms of purple rice extract on testosterone‐induced rat benign prostatic hyperplasia. Such information, purple rice components show promise as an effective chemopreventive agent for prostatic hyperplasia prevention by alternating the influence of testosterone through its receptor. Thus, purple rice might be developed as food supplement for reduction of prostatic hyperplasia or cancer in elder men.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.